Antithrombotic therapy - predictor of early and longterm bleeding complications after transcatheter aortic valve implantation

Archives of Medical Science

Volumn 9, Issue 6, 2013, Pages 1062-1070

  Czerwiñska Jelonkiewicz, Katarzyna ^a   Witkowski, Adam ^a   Da̧browski, Maciej ^a   Banaszewski, Marek ^a   Ksiȩzycka Majczyñska, Ewa ^a   Chmielak, Zbigniew ^a   Kuœmierski, Krzysztof ^a   Hryniewiecki, Tomasz ^a   Demkow, Marcin ^a   Orłowska Baranowska, Ewa ^a   Stȩpiñska, Janina ^a  

^a INSTITUTE OF CARDIOLOGY   (Poland)

Author keywords

Antithrombotic prophylaxis; Aortic stenosis; Bleeding complications; Transcatheter aortic valve implantation

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; CLOPIDOGREL; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

AGED; ANEMIA; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BODY MASS; DEEP VEIN THROMBOSIS; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; RISK ASSESSMENT; SURVIVAL; THROMBOEMBOLISM; TRANSCATHETER AORTIC VALVE IMPLANTATION; VERY ELDERLY;

EID: 84892398134     PISSN: 17341922     EISSN: 18969151     Source Type: Journal    
DOI: 10.5114/aoms.2013.39794     Document Type: Article

References (26)

1. Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease. The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2012; 33: 2451-96.
2. Vahanian A, Alfieri O, Al-Attar N, et al. Transcatheter valve implantation for patients with aortic stenosis: A position statement from the European Association of Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2008; 29: 1463-70.
3. Ussia GP, Scarabelli M, Mule M, et al. Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation. Am J Cardiol 2011; 108: 1772-6.
4. Stabile E, Sorropago E, Pucciarelli A, et al. SAT-TAVI (Single Antiplatelet Therapy for TAVI) study: A randomized study comparing double to single antiplatelet therapy for transcatheter aortic valve implantation. J Am Coll Cardiol 2011; 58: Suppl B.
5. Kappetein A, Stuart J, Genereux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: The Valve Academic Research Consortium-2 consensus document. Eur Heart J 2012; 33: 2403-18.
6. Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. New Eng J Med 2011; 364: 2187-98.
7. Kodali SK, Williams MR, Smith CR, et al. Two-year out-comes after transcatheter or surgical aortic-valve replacement. New Engl J Med 2012; 366: 1686-95.
8. Ussia GP, Barbanti M, Petronio AS, et al. Transcatheter aortic valve implantation: 3-year outcomes of selfexpanding CoreValve prosthesis. Eur Heart J 2012; 33: 969-76.
9. Halliday BP, Dworakowski R, Brickham B, Wendler O, MacCarthy P. Usefulness of periprocedural bleeding to predict outcome after transcatheter aortic valve implantation. Am J Cardiol 2012; 109: 724-8.
10. Van Mieghem NM, Nuis RJ, Tzikas A, et al. Prevalence and prognostic implications of baseline anaemia in patients undergoing transcatheter aortic valve implantation. EuroIntervention 2011; 7: 184-91.
11. Tchetche D, Van Der Boon RM, Dumonteli N, et al. Adverse impact of bleeding and transfusion on the outcome posttranscatheter aortic valve implantation: Insights from the Pooled-RotterdAm-Milano-Toulouse In Collaboration Plus (PRAGMATIC Plus) initiative. Am Heart J 2012; 164: 402-9.
12. Czerwinska K, Orowska-Baranowska E, Witkowski A, et al. Transapical aortic valve implantation-a rescue procedure for patients with aortic stenosis and "porcelain aorta". Arch Med Sci 2011; 7: 528-32.
13. Borz B, Durand E, Godin M, et al. Incidence, predictors and impact of bleeding after transcatheter aortic valve implantation using the balloon-expandable Edwards prosthesis. Heart 2013; 99: 860-5.
14. Moreno R, Calvo L, Salinas P, et al. Causes of perioperative mortality after transcatheter aortic valve implantation: A pooled analysis of 12 studies and 1223 patients. J Invasive Cardiol 2011; 23: 180-4.
15. Genereux P, Head SJ, Van Mieghem NM, et al. Clinical outcomes after transcatheter aortic valve replacement using valve academic research consortium definitions: A weighted meta-analysis of 3,519 patients from 16 studies. J Am Coll Cardiol 2012; 59: 2317-26.
16. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
17. Karjalainen PP, Vikman S, Niemela M, et al. Safety of PCI during uninterrupted oral anticoagulant treatment. Eur Heart J 2008; 29: 1001-10.
18. Manzano-Fernandez S, Pastor FJ, Marin F, et al. Increased major bleeding complications related to triple anti-thrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting. Chest 2008; 134: 559-67.
19. Zhao HJ, Zheng ZT, Wang ZH, et al. ''Triple therapy'' rather than ''triple threat'': A meta-analysis of the two anti-thrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment. Chest 2011; 139: 260-70.
20. Hansen ML, Sorensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Inter Med 2010; 170: 1433-41.
21. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Developed with the special contri-bution of the European Heart Rhythm Association (EHRA) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010; 31: 2369-429.
22. Rashi A, Downes T, Portner R, Yeo WW, Morgan N, Channer KS. A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation. Age Ageing 2007; 36: 151-6.
23. Pfeffer MA, Hohnloser SH, De Caterina R, Flaker G, Sand Y, Connolly SJ. Risks and benefits of oral anti-coagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: The Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE-W). Stroke 2008; 39: 1482-6.
24. Wijns W, Kolh P, Danchin N, et al. Guidelines on myo-cardial revascularization. The Task Force on Myo cardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association for Percutaneous Cardio-vascular Interventions (EAPCI). Eur Heart J 2010; 31: 2501-55.
25. Dewilde W, Oirbans T, Verheugt F, et al. Use of clopidogrel with or without aspirin in patients taking oral anti-coagulant therapy and undergoing percutaneous coronary intervention: An open-label, randomised, controlled trial. Lancet 2013; 381: 1107-15.
26. Mehta RH, Roe MT, Mulgund J, et al. Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery. J Am Coll Cardiol 2006; 48: 281-6.